Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO is ...

The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish ...

智通财经APP注意到，Ozempic 和 Wegovy 为 诺和诺德 (NVO.US)公司赚取了巨额利润，它们的累计销售额很快就会超过这家制药商过去 30 年的全部研发预算。而 ...

​丹麦制药巨头诺和诺德被质疑旗下两款药品定价太贵！周二，诺和诺德高管因公司减肥药Wegovy和糖尿病治疗药物Ozempic价格过高而接受参议院质询。参议院小组主席伯尼·桑德斯认为，诺和诺德对美国患者收取的费用远远高于其他国家。对此，诺和诺德辩解称，这是因为要给美国药品福利管理者（PBM）支付高昂回扣。被吐槽定价太贵 ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

智通财经注意到，Ozempic 和 Wegovy 为诺和诺德（NVO.US）公司赚取了巨额利润，它们的累计销售额很快就会超过这家制药商过去 30 ...

但弗雷德里克森否认了所谓的诺基亚风险与诺和诺德之间的联系。诺和诺德的市值约为5,700亿美元，超过了丹麦的年度GDP。然而，弗雷德里克森在哥本哈根接受彭博电视采访时表示，丹麦经济在“相当长一段时间”内一直依赖熟练的劳动力和广泛成功的企业保持强劲。

格隆汇9月25日｜丹麦制药巨头诺和诺德CEO Lars ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

丹麦制药商诺和诺德(NVO.US)因旗下减肥药Wegovy和糖尿病药Ozempic的高定价而面临美国参议院质询。诺和诺德首席执行官Lars Fruergaard Jorgensen将於美国东部时间周二...